X-ray analysis deciphers master regulator important for skin cancer

December 1, 2012

With the X-ray vision of DESY's light source DORIS, a research team from Hamburg and Iceland has uncovered the molecular structure of a master regulator central to the most deadly form of skin cancer, melanoma. The results, published in the scientific journal Genes & Development, throw new light on the workings of the so-called Microphthalmia-associated Transcription Factor MITF, that is not only connected to skin cancer, but also to a variety of hereditary diseases where the production of the skin pigment melanin is disturbed, and to certain aspects of ageing.

"Our data could provide a rational basis for the development of tailor-made drugs targeting MITF", explains first author Vivian Pogenberg from the Hamburg branch of the European Molecular Biology Laboratory (EMBL). Deutsches Elektronen-Synchrotron DESY is the leading German accelerator centre and one of the leading in the world. Among other things, DESY develops and provides accelerator based light sources for research.

is a malignant tumor of the cells that produce the skin pigment melanin, the melanocytes. It is not the most common form of but the one with the greatest death toll by far: about 3 out of 4 skin cancer related deaths are caused by melanoma. Important for the development of melanoma are malfunctions of the Microphtalmia-associated Transcription Factor MITF. regulate which part of the DNA is read and transcribed into a blueprint for a protein within the cell. Only few parts of the DNA are active in each cell, and this activity also changes with time. MITF for instance activates the cell's machinery to turn the amino acid tyrosine into the pigment melanin.

But MITF also makes stem cells turn into melanocytes in the first place and controls cell proliferation and death in these cells. That's why MITF is called a master regulator. In fact, it also has functions in other cell types like mast cells of the immune system and bone eating osteoclasts. Mutations in MITF not only play a role in the development of skin cancer, but also cause severe genetic diseases like the Tietz and Waardenburg syndromes that lead to deafness, skin and hair pigmentation defects, abnormal eye anatomy and altered vision. The transcription factor also plays a role in our hair turning grey with age and other age-related pigmentation alterations.

The researchers crystallised MITF in the lab and x-rayed them with DORIS. Crystals scatter X-rays in characteristic ways and produce diffraction patterns from which the structure of the crystal - and here MITF - can be reconstructed. The analysis revealed unexpected molecular insertions that give MITF a unique kink. MITF forms a dimer with a long coiled-coil protein "zipper", and the kink in this zipper limits MITF's ability to bind to other transcription factors. The team could also identify structural changes caused by a number of MITF mutations known to lead to particular coat colours in mice and to Tietz or Waardenburg syndrome in humans. The different forms of MITF were supplied by the University of Iceland, where the lab of Eiríkur Steingrímsson hosts a comprehensive MITF library. Steingrímsson also provided his expertise in cell biology and genetics to support the structural data produced in Hamburg.

Thanks to the structural information from DORIS the team could also investigate the binding site of MITF to the DNA at the European Synchrotron Radiation Facility (ESRF) in Grenoble, France. The analysis revealed for instance that the eponymous mutation (the one leading to white coats and small eyes - or microphthalmia - in mice) causes structural changes in the MITF that prevents it from binding to the DNA. Other mutations also affect the binding site to the DNA, making MITF bind to the wrong . "Ultimately the goal will be to fully understand how MITF functions to evaluate how it can be targeted for potential treatment", says Matthias Wilmanns, a group leader at EMBL Hamburg. "One way would be, for instance, to design molecules that specifically stop MITF dimerisation in melanocytes," explains Pogenberg. "Or, on an alternative route, a different custom made molecule could stop the recognition of DNA by MITF."

Explore further: Newly identified gene mutation adds to melanoma risk

More information: Restricted leucine zipper dimerization and specificity of DNA recognition of the melanocyte master regulator MITF; Vivian Pogenberg et al.; "Genes & Development", 2012; DOI: 10.1101/gad.198192.112

Related Stories

Newly identified gene mutation adds to melanoma risk

November 13, 2011
A major international study has identified a novel gene mutation that appears to increase the risk of both inherited and sporadic cases of malignant melanoma, the most deadly form of skin cancer. The identified mutation occurs ...

Genetics of melanoma chemoresistance

June 6, 2011
Malignant melanoma is a highly aggressive and notoriously chemoresistant form of cancer. In a new paper, Ohanna et al. reveal that anti-melanoma drugs may, paradoxically, induce a senescence-associated secretory profile ("secretome") ...

Recommended for you

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.